What is Overture Life?
Overture Life is at the forefront of revolutionizing embryology and IVF procedures through a sophisticated integration of engineering, reproductive medicine, and rigorous validation. The company's innovative approach focuses on enhancing egg freezing and embryo handling processes, aiming to reduce the cost of IVF, increase laboratory throughput, and minimize the need for repeated treatment cycles. With a dual presence in R&D in Spain and operational activities in the U.S., including a CLIA-licensed laboratory for advanced non-invasive embryo selection, Overture Life leverages robotics, data analytics, and clinical expertise. Its flagship DaVitri platform is designed to bolster reliability and consistency in IVF, empowering clinics and patients globally with greater control over fertility timelines.
How much funding has Overture Life raised?
Overture Life has raised a total of $55.6M across 3 funding rounds:
Series A
$20M
Series B
$15M
Other Financing Round
$20.6M
Series A (2019): $20M with participation from Allen & Comapany, Anne Wojcicki, Felicis Ventures, Khosla Ventures, Rakuten, and Marc Benioff
Series B (2021): $15M led by Felicis Ventures, GV, Khosla Ventures, and Octopus Ventures
Other Financing Round (2025): $20.6M supported by GV, Overwater Ventures, and Khosla Ventures
Key Investors in Overture Life
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a focus on enterprise solutions, life sciences, and frontier technology innovations. They provide financial backing to promising startups and growth-stage businesses globally.
Overwater Ventures
Overwater Ventures partners with pre-seed and seed stage founders addressing significant global challenges, offering support in commercialization and scaling. They emphasize strong founder relationships and provide extensive networking opportunities.
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing companies aiming to change the world across software, climate, health, consumer, and financial technology, offering long-term capital and guidance.
What's next for Overture Life?
The recent major strategic investment signals a new phase of growth and development for Overture Life, positioning it for significant scaling within the competitive fertility technology market. This capital will likely be directed towards expanding its technological capabilities, further refining its DaVitri platform, and broadening its market reach. As Overture Life continues to innovate in areas like robotics and analytics for embryology, its strategic backing from prominent investors suggests a strong market validation and a clear path toward becoming a leader in fertility solutions. The company's focus on increasing efficiency and reducing costs in IVF aligns with growing global demand for accessible and effective fertility treatments.
See full Overture Life company page
